L. Torre, F. Bray, R. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, 2012, Global cancer statistics, pp.87-108, 2012.
DOI : 10.1002/ijc.29210

P. Bertuccio, C. Bosetti, F. Levi, A. Decarli, E. Negri et al., A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe, Annals of Oncology, vol.24, issue.6, pp.1667-1674, 2013.
DOI : 10.1093/annonc/mds652

H. El-serag and K. Rudolph, Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis, Gastroenterology, vol.132, issue.7, pp.2557-2576, 2007.
DOI : 10.1053/j.gastro.2007.04.061

P. Almasio, G. Venezia, and A. Craxi, The impact of antiviral therapy on the course of chronic HCV infection: A systematic review, Journal of Hepatology, vol.38, issue.3, pp.175-182, 2003.
DOI : 10.1016/S0168-8278(03)80689-X

F. Turati, C. Galeone, M. Rota, C. Pelucchi, E. Negri et al., Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies, Annals of Oncology, vol.25, issue.8, 2014.
DOI : 10.1093/annonc/mdu020

A. Sanyal, A. Poklepovic, E. Moyneur, and V. Barghout, Population-based risk factors and resource utilization for HCC: US perspective, Current Medical Research and Opinion, vol.26, issue.9, pp.2183-2191, 2010.
DOI : 10.1185/03007995.2010.506375

M. Noureddin and M. Rinella, Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma, Clinics in Liver Disease, vol.19, issue.2, pp.361-379, 2015.
DOI : 10.1016/j.cld.2015.01.012

P. Wang, D. Kang, W. Cao, Y. Wang, and Z. Liu, Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis, Diabetes/Metabolism Research and Reviews, vol.282, issue.11, 2012.
DOI : 10.1002/dmrr.1291

S. Singh, P. Singh, A. Singh, M. Murad, and W. Sanchez, Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis, The American Journal of Gastroenterology, vol.30, issue.6, pp.881-91, 2013.
DOI : 10.1038/ajg.2013.5

S. Larsson and A. Wolk, Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies, British Journal of Cancer, vol.55, issue.7, pp.1005-1008, 2007.
DOI : 10.1016/j.gastro.2004.09.018

M. Elmberg, R. Hultcrantz, A. Ekbom, L. Brandt, S. Olsson et al., Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives, Gastroenterology, vol.125, issue.6, pp.1733-1741, 2003.
DOI : 10.1053/j.gastro.2003.09.035

Y. Liang, Z. Yang, and R. Zhong, Primary biliary cirrhosis and cancer risk: A systematic review and meta-analysis, Hepatology, vol.50, issue.4, pp.1409-1417, 2012.
DOI : 10.1002/hep.25788

S. Van-meer, R. De-man, P. Siersema, and K. Van-erpecum, Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies, World J Gastroenterol, 2013.

Y. Cho, J. Kim, M. Kim, H. Rhim, and J. Han, Systematic review of randomized trials for

R. Salem, R. Lewandowski, M. Mulcahy, A. Riaz, R. Ryu et al., Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes, Gastroenterology, vol.138, issue.1, pp.52-64, 2010.
DOI : 10.1053/j.gastro.2009.09.006

R. Salem, R. Lewandowski, L. Kulik, E. Wang, A. Riaz et al., Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma, Gastroenterology, vol.140, issue.2, pp.497-507, 2011.
DOI : 10.1053/j.gastro.2010.10.049

R. Poon, T. Cheung, P. Kwok, A. Lee, T. Li et al., Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma, Liver Cancer, vol.4, issue.1, 2015.
DOI : 10.1159/000367728

B. Wang, H. Xu, Z. Gao, H. Ning, Y. Sun et al., Increased Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization, Acta Radiologica, vol.49, issue.5, pp.523-529, 2008.
DOI : 10.1080/02841850801958890

S. Virmani, T. Rhee, R. Ryu, K. Sato, R. Lewandowski et al., Comparison of Hypoxia-inducible Factor-1?? Expression before and after Transcatheter Arterial Embolization in Rabbit VX2 Liver Tumors, Journal of Vascular and Interventional Radiology, vol.19, issue.10, pp.1483-1489, 2008.
DOI : 10.1016/j.jvir.2008.06.017

R. Lencioni, Chemoembolization for Hepatocellular Carcinoma, Seminars in Oncology, vol.39, issue.4, 2012.
DOI : 10.1053/j.seminoncol.2012.05.004

URL : https://hal.archives-ouvertes.fr/hal-01134844

Q. Fu, Q. Zhang, X. Bai, Q. Hu, W. Su et al., Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis, Journal of Cancer Research and Clinical Oncology, vol.9, issue.2, pp.1429-1440, 2014.
DOI : 10.1007/s00432-014-1684-5

W. Sieghart, M. Pinter, M. Reisegger, C. Muller, A. Ba-ssalamah et al., Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study, European Radiology, vol.33, issue.6, pp.1214-1223, 2012.
DOI : 10.1007/s00330-011-2368-z

Y. Chao, Y. Chung, G. Han, J. Yoon, Y. J. Wang et al., The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial, International Journal of Cancer, vol.15, issue.6, pp.1458-1467, 2015.
DOI : 10.1002/ijc.29126

A. Bouvier, V. Ozenne, C. Aube, J. Boursier, M. Vullierme et al., Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival, European Radiology, vol.39, issue.8, pp.1719-1726, 2011.
DOI : 10.1007/s00330-011-2118-2

M. Varela, M. Real, M. Burrel, A. Forner, M. Sala et al., Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics, Journal of Hepatology, vol.46, issue.3, pp.474-481, 2007.
DOI : 10.1016/j.jhep.2006.10.020

K. Malagari, M. Pomoni, H. Moschouris, E. Bouma, J. Koskinas et al., Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival Analysis, CardioVascular and Interventional Radiology, vol.23, issue.6, pp.1119-1128, 2012.
DOI : 10.1007/s00270-012-0394-0

K. Takayasu, S. Arii, M. Kudo, T. Ichida, O. Matsui et al., Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines, Journal of Hepatology, vol.56, issue.4, pp.886-892, 2012.
DOI : 10.1016/j.jhep.2011.10.021

J. Park, M. Chen, M. Colombo, L. Roberts, M. Schwartz et al., Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study, Liver International, vol.38, issue.Suppl 1, 2015.
DOI : 10.1111/liv.12818

J. Raoul, B. Sangro, A. Forner, V. Mazzaferro, F. Piscaglia et al., Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization, Cancer Treatment Reviews, vol.37, issue.3, pp.212-220, 2011.
DOI : 10.1016/j.ctrv.2010.07.006

URL : https://hal.archives-ouvertes.fr/hal-01134844

K. Han, M. Kudo, S. Ye, J. Choi, R. Poon et al., Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia, Oncology, vol.81, issue.s1, pp.158-164, 2011.
DOI : 10.1159/000333280

K. Takayasu, S. Arii, I. Ikai, M. Omata, K. Okita et al., Prospective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 Patients, Gastroenterology, vol.131, issue.2, pp.461-469, 2006.
DOI : 10.1053/j.gastro.2006.05.021

J. Bruix, J. Llovet, A. Castells, X. Montana, C. Bru et al., Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution, Hepatology, vol.167, issue.Suppl, 1998.
DOI : 10.1002/hep.510270617

K. Ahrar and S. Gupta, Hepatic artery embolization for hepatocellular carcinoma: technique, patient selection, and outcomes, Surgical Oncology Clinics of North America, vol.12, issue.1, pp.105-126, 2003.
DOI : 10.1016/S1055-3207(02)00089-3

R. Poon, H. Ngan, C. Lo, C. Liu, S. Fan et al., Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence, Journal of Surgical Oncology, vol.43, issue.2, pp.109-114, 2000.
DOI : 10.1002/(SICI)1096-9098(200002)73:2<109::AID-JSO10>3.0.CO;2-J

R. Lencioni and J. Llovet, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010 Feb, pp.52-60

R. Gillmore, S. Stuart, A. Kirkwood, A. Hameeduddin, N. Woodward et al., EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization, Journal of Hepatology, vol.55, issue.6, 2011.
DOI : 10.1016/j.jhep.2011.03.007

E. Jung, J. Kim, E. Yoon, H. Lee, S. Lee et al., Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization, Journal of Hepatology, vol.58, issue.6, pp.1181-1187, 2013.
DOI : 10.1016/j.jhep.2013.01.039

G. Antoch, G. Roelle, S. Ladd, H. Kuehl, T. Heusner et al., Selective and sequential transarterial chemoembolization: Survival in patients with hepatocellular carcinoma, European Journal of Radiology, vol.81, issue.9, pp.2290-2297, 2012.
DOI : 10.1016/j.ejrad.2011.09.010

J. Bruix, M. Reig, J. Rimola, A. Forner, M. Burrel et al., Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques, Hepatology, vol.365, issue.Suppl, pp.2238-2244, 2011.
DOI : 10.1002/hep.24670

C. Georgiades, J. Geschwind, N. Harrison, A. Hines-peralta, E. Liapi et al., Lack of Response after Initial Chemoembolization for Hepatocellular Carcinoma: Does It Predict Failure of Subsequent Treatment?, Radiology, vol.265, issue.1, pp.115-123, 2012.
DOI : 10.1148/radiol.12112264

H. Kim, J. Park, J. Joo, S. Jung, S. An et al., Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, vol.53, issue.6, pp.1051-1056, 2012.
DOI : 10.1111/j.1440-1746.2011.06963.x

A. Forner, M. Gilabert, J. Bruix, and J. Raoul, Treatment of intermediate-stage hepatocellular carcinoma, Nature Reviews Clinical Oncology, vol.32, issue.9, pp.525-535, 2014.
DOI : 10.1016/S0140-6736(11)61347-0

L. Kadalayil, R. Benini, L. Pallan, O. Beirne, J. Marelli et al., A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer, Annals of Oncology, vol.24, issue.10
DOI : 10.1093/annonc/mdt247

L. Bolondi, A. Burroughs, J. Dufour, P. Galle, V. Mazzaferro et al., Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions, Semin Liver Dis, vol.32, issue.4, pp.348-359, 2012.

W. Sieghart, F. Hucke, M. Pinter, I. Graziadei, W. Vogel et al., The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma, Hepatology, vol.262, issue.Suppl 4, pp.2261-2273, 2013.
DOI : 10.1002/hep.26256

X. Adhoute, G. Penaranda, S. Naude, J. Raoul, H. Perrier et al., Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process, Journal of Hepatology, vol.62, issue.4, pp.855-862
DOI : 10.1016/j.jhep.2014.11.014

F. Hucke, M. Pinter, I. Graziadei, S. Bota, W. Vogel et al., How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma, Journal of Hepatology, vol.61, issue.6, pp.1287-1296, 2014.
DOI : 10.1016/j.jhep.2014.07.002

C. Roxburgh and D. Mcmillan, Role of systemic inflammatory response in predicting survival in patients with primary operable cancer, Future Oncology, vol.6, issue.1, pp.149-163, 2010.
DOI : 10.2217/fon.09.136

S. Nagaoka, T. Yoshida, J. Akiyoshi, J. Akiba, T. Torimura et al., Serum Creactive protein levels predict survival in hepatocellular carcinoma, Liver Int, 2007.

K. Hashimoto, Y. Ikeda, D. Korenaga, K. Tanoue, M. Hamatake et al., The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma, Cancer, vol.37, issue.9, pp.1856-1864, 2005.
DOI : 10.1002/cncr.20976

A. Kinoshita, H. Onoda, N. Imai, A. Iwaku, M. Oishi et al., The addition of Creactive protein to validated staging systems improves their prognostic ability in patients with hepatocellular carcinoma, Oncology, vol.86, pp.5-6308, 2014.

T. Chen, C. Lin, P. Huang, and C. Wen, Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation, Journal of Gastroenterology and Hepatology, vol.29, issue.7, pp.553-561, 2012.
DOI : 10.1111/j.1440-1746.2011.06910.x

G. Xiao, C. Liu, D. Liu, J. Yang, and L. Yan, Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation, World Journal of Gastroenterology, vol.19, issue.45, pp.8398-8407, 2013.
DOI : 10.3748/wjg.v19.i45.8398

L. Da-fonseca, R. Barroso-sousa, B. Ada, S. Blanco, B. Valente et al., Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib, Medical Oncology, vol.7, issue.8, pp.264-278, 2014.
DOI : 10.1007/s12032-014-0264-5

F. Gao, X. Li, M. Geng, X. Ye, H. Liu et al., Pretreatment Neutrophil???Lymphocyte Ratio, Medicine, vol.94, issue.11
DOI : 10.1097/MD.0000000000000639

W. Fan, Y. Zhang, Y. Wang, X. Yao, Y. J. Li et al., Neutrophil-to-lymphocyte and plateletto-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization, PLoS One, vol.10, issue.3, p.119312, 2015.

Y. Ha, J. H. Shim, S. O. Kim, K. M. Kim, Y. S. Lim et al., Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis, Journal of Gastroenterology and Hepatology, vol.33, issue.Suppl. 3, pp.787-793, 2014.
DOI : 10.1111/jgh.12452

F. Waneck, M. Trauner, and M. Peck-radosavljevic, The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE, J.Hepatol, vol.60, issue.1, pp.118-126, 2014.